Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:11:33.013Z.
Consensus retrieved: 2026-10-06T10:54:44.081Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:11:33.013Z.
Quote observation: 2026-10-06T19:09:36.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7
Forward PE Ratio (N/A) = Dated Quote Price ($14.58) / Consensus Forward EPS ($-0.96)
FORWARD PE RATIO
N/A
Alpha Tau Medical Ltd
Market Cap
$1.32B
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Alpha Tau Medical Ltd (DRTS) | $1.32B | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.33B | N/A |
| Omeros Corporation (OMER)vs › | $1.34B | 20.44 |
| Kardigan, Inc. (KARD)vs › | $1.26B | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.38B | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.39B | 28.67 |
| ORIC Pharmaceuticals, Inc. (ORIC)vs › | $1.23B | N/A |
| Omada Health (OMDA)vs › | $1.23B | N/A |
| Kailera Therapeutics, Inc. (KLRA)vs › | $1.41B | N/A |
| Braveheart Bio, Inc. (BRVE)vs › | $1.41B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $14.58, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.96 | $-0.98 – $-0.93 | 4 | n/m |
| 2027-12-31 | $-0.53 | $-0.58 – $-0.49 | 4 | n/m |
| 2028-12-31 | $-0.37 | $-0.58 – $-0.16 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
